Development and Validation of the ELISA Method for Anti-trastuzumab Antibodies Determination in Human Serum

Development and Validation of the ELISA Method for Anti-trastuzumab Antibodies Determination in Human Serum

Introduction. One of the widely used specific anti-HER2 (human epidermal growth factor receptor 2) MAb drugs is trastuzumab. Trastuzumab is highly effective for malignant HER2 hyperexpression reduction, which results in HER2 oncogenicity decrease. As any other biotherapeutics trastuzumab can cause i...

Full description

Saved in:
Bibliographic Details
Main Authors: O. A. Eliseeva, M. A. Kolganova, I. E. Shokhin, S. P. Dementyev, A. M. Vlasov, A. A. Zamyatnin, N. S. Dubovik, A. Yu. Savchenko, N. V. Dozmorova, V. G. Luzhanin
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2022-12-01
Series:Разработка и регистрация лекарственных средств
Subjects:
trastuzumab
immunogenicity
biosimilars
elisa
Online Access:https://www.pharmjournal.ru/jour/article/view/1408
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmjournal.ru/jour/article/view/1408

Similar Items